Model-Based Optimal Design and Execution of the First-Inpatient Trial of the Anti-IL-6, Olokizumab

The first-in-patient study for olokizumab (OKZ) employed model-based, optimal design and adaptive execution to define the concentration–C-reactive protein (CRP) suppression response. Modeling and exploratory statistics activities involved: reverse engineering of first-in-class (tocilizumab) pharmaco...

Descripción completa

Detalles Bibliográficos
Autores principales: Kretsos, K, Jullion, A, Zamacona, M, Harari, O, Shaw, S, Boulanger, B, Oliver, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076804/
https://www.ncbi.nlm.nih.gov/pubmed/24941311
http://dx.doi.org/10.1038/psp.2014.17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076804/
https://www.ncbi.nlm.nih.gov/pubmed/24941311
http://dx.doi.org/10.1038/psp.2014.17

Ejemplares similares